MEI Pharma 8-K: Officer/Director Changes, Comp Arrangements
Ticker: LITS · Form: 8-K · Filed: Jan 17, 2024 · CIK: 1262104
| Field | Detail |
|---|---|
| Company | Mei Pharma, INC. (LITS) |
| Form Type | 8-K |
| Filed Date | Jan 17, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.00000002, $503,165 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: executive-changes, compensation, corporate-governance
TL;DR
**MEIP filed an 8-K about executive changes and pay, details to follow.**
AI Summary
MEI Pharma, Inc. filed an 8-K on January 17, 2024, reporting an event that occurred on January 16, 2024, related to changes in its directors or officers and their compensation arrangements. This filing indicates potential shifts in leadership or executive compensation, which could impact the company's strategic direction and financial health. Investors should monitor subsequent filings for details on who departed or was appointed, and the specifics of any new compensatory arrangements, as these changes can signal confidence or concern within the company's management.
Why It Matters
Changes in executive leadership and compensation can significantly influence a company's future performance and investor confidence. New leadership might bring fresh strategies, while altered compensation could reflect performance incentives or cost-cutting measures.
Risk Assessment
Risk Level: medium — Without specific details on who departed or was appointed, and the nature of compensatory arrangements, the impact on the company's stability and future direction is uncertain.
Analyst Insight
A smart investor would await further detailed disclosures from MEI Pharma, Inc. regarding the specific individuals involved in the reported changes and the terms of any new compensatory arrangements before making investment decisions, as this filing only signals an event without providing specifics.
Key Players & Entities
- MEI Pharma, Inc. (company) — the registrant filing the 8-K
- January 16, 2024 (date) — date of the earliest event reported
- January 17, 2024 (date) — date the 8-K was filed
- 001-41827 (other) — Commission File Number for MEI Pharma, Inc.
- 51-0407811 (other) — IRS Employer Identification No. for MEI Pharma, Inc.
FAQ
What specific event did MEI Pharma, Inc. report in this 8-K filing?
MEI Pharma, Inc. reported an event concerning the 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers' on January 16, 2024.
When was this 8-K filing submitted to the SEC?
The 8-K filing was submitted to the SEC on January 17, 2024, as indicated by the 'FILED AS OF DATE' and 'DATE AS OF CHANGE'.
What is the business address of MEI Pharma, Inc.?
The business address of MEI Pharma, Inc. is 11455 El Camino Real, Suite 250, San Diego, California, 92130.
What is the trading symbol and exchange for MEI Pharma, Inc.'s Common Stock?
MEI Pharma, Inc.'s Common Stock trades under the symbol 'MEIP' on The Nasdaq Stock Market LLC.
What is the fiscal year end for MEI Pharma, Inc.?
MEI Pharma, Inc.'s fiscal year ends on June 30, as stated in the 'FILER' section of the filing.
Filing Stats: 933 words · 4 min read · ~3 pages · Grade level 12.9 · Accepted 2024-01-17 16:00:08
Key Financial Figures
- $0.00000002 — nge on which registered Common Stock, $0.00000002 par value MEIP The Nasdaq Stock Mar
- $503,165 — ovides for (i) an annual base salary of $503,165.28, (ii) a target annual bonus opportun
Filing Documents
- meip-20240116.htm (8-K) — 40KB
- 0000950170-24-005013.txt ( ) — 148KB
- meip-20240116.xsd (EX-101.SCH) — 23KB
- meip-20240116_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 17, 2024 By: /s/ David M. Urso President and Chief Executive Officer